<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784692</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0255</org_study_id>
    <nct_id>NCT01784692</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals</brief_title>
  <official_title>Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a small study aimed at determining the effects of oral Immulina consumption on
      the immune system in elderly individuals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Interferon gamma (IFNg)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase in IFNg from baseline to 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological Measures</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effects of Immulina on immune biomarkers based upon psychological differences including perceived stress, anxiety, depression and worry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal supplement regime</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Optimizing Immulina dose for maximal immune biomarker levels observing changes in Treg, Tr1, Th3, T Helper1, T Helper 2 cells, salivary cortisol, salivary alpha amylase, Interleukin 4 and Interleukin 10 cytokine production from baseline to 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic differences</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effects of Immulina based upon demographic differences including gender, race, age, BMI and socioeconomic status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Treg, Tr1, Th3, T Helper 1, T Helper 2 cells, salivary cortisol, salivary alpha amylase, Interleukin 4 and Interleukin 10 cytokine production from baseline to 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Elderly Immune Senescence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Immulina 200 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 participants will be randomized to take 200 mg/day of Immulina.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immulina 400 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 participants will be randomized to take 400 mg/day of Immulina.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immulina 800 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 participants will be randomized to take 800 mg/day of Immulina.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immulina</intervention_name>
    <arm_group_label>Immulina 200 mg/day</arm_group_label>
    <arm_group_label>Immulina 400 mg/day</arm_group_label>
    <arm_group_label>Immulina 800 mg/day</arm_group_label>
    <other_name>Spirulina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 60 and older;

          -  Generally otherwise healthy for age and not taking medications/supplements that could
             be expected to affect stress responses and/or impact immune parameters (example -
             systemic steroids, beta blockers, antidepressants, anti-anxiety drugs, Echinacea
             supplements, ginseng supplements or Spirulina supplements).

        Exclusion Criteria:

          -  Inability to comprehend and speak English;

          -  Any history of major psychological or psychiatric illness (example - dementia,
             psychotic disorder, acute mania, current substance abuse) that may limit participant
             cooperation or compromise the integrity of self-reported clinical or psychological
             data;

          -  Presence of a confounding underlying systemic illness which could interfere with
             immunological profiles (example - severe cardiovascular, pulmonary, hepatic,
             gastrointestinal, renal, neurological, musculoskeletal endocrine , or metabolic
             systems; other gross physical impairments; or any history of significant convulsive
             disorder).  Specifically, patients with congestive heart failure, recent viral or
             bacterial illness in the past 3 weeks, chronic kidney disease, thyroid disorder,
             autoimmune disease will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gailen D. Marshall, Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise D. Montgomery, MT(ASCP)</last_name>
    <phone>601-815-5374</phone>
    <email>ddmontgomery@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise D. Montgomery, MT(ASCP)</last_name>
      <phone>601-815-5374</phone>
      <email>ddmontgomery@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Gailen D. Marshall, Jr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Gailen D. Marshall</investigator_full_name>
    <investigator_title>Professor of Medicine and Pediatrics, Vice Chair for Research, Department of Medicine, Director, Division of Clinical Immunology and Allergy, Chief, Laboratory of Behavioral Immunology Research</investigator_title>
  </responsible_party>
  <keyword>Immulina</keyword>
  <keyword>Elderly</keyword>
  <keyword>Immune</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
